journal article·2026-08Open access

Curcumin-loaded tetrahedral framework nucleic acids reshape intestinal homeostasis in ulcerative colitis by coordinating barrier repair, microbiota reconstruction, and immune modulation

Meng Li, Xiaomeng Yue, Qiangwei Liu, Jifang Cui, Yandi Liu, Liujie Zhao, Lin Yang, Zejie Liu, Muran Li, Jiaojiao Yu, Shao-Kai Sun

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) primarily driven by oxidative stress, sustained inflammation, barrier dysfunction, and gut dysbiosis. Current therapeutic drugs face limitations including complex synthetic processes, significant side effects, and suboptimal efficacy. Herein, we propose a simple, safe, and high-efficiency therapeutic strategy using curcumin-loaded tetrahedral framework nucleic acids (tFNAs-Cur) to reshape intestinal homeostasis in UC by coordinating barrier repair, microbiota reconstruction, and antigen presentation modulation. The synthesized tFNAs-Cur demonstrated high Cur loading, stability, water solubility, and biocompatibility. At the cellular level, tFNAs-Cur is efficiently taken up by lipopolysaccharide-stimulated RAW264.7 cells, exerting potent antioxidant and anti-inflammatory effects. In the dextran-sulfate-sodium-induced UC mouse model, tFNAs-Cur shows enhanced colon accumulation, attenuates weight loss and disease activity index, preserves colon length, repairs intact crypt architecture, and thereby restores intestinal barrier function. Further transcriptomic and biochemical analyses reveal that tFNAs-Cur alleviates IBD by upregulating H2-DMb1, potentially enhancing antigen presentation, while concurrently suppressing pro-inflammatory factors (TNF-α, IL-6, NO) and promoting anti-inflammatory cytokine IL-10. Additionally, 16S rRNA sequencing shows that tFNAs-Cur restores a healthy gut microbiota by enriching probiotic Muribaculaceae and suppressing pro-inflammatory bacteria. Collectively, tFNAs-Cur presents a safe, readily translatable, and efficient clinical candidate for UC by coordinating multiple synergistic mechanisms.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inflammatory Bowel Disease · Curcumin's Biomedical Applications · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (75)

Show source-provided references
1. Ulcerative colitis10.1038/s41572-020-0205-x ↗
2. Oral HMPB/Mn3O4 nanozymes for the treatment of ulcerative colitis via cellular redox balance regulation, gut microbiota modulation, and ferroptosis inhibition
3. Orally administrated inflamed colon-targeted nanotherapeutics for inflammatory bowel disease treatment by oxidative stress level modulation in colitis10.1021/acsnano.3c11089 ↗
4. Low-input redoxomics facilitates global identification of metabolic regulators of oxidative stress in the gut10.1038/s41392-024-02094-7 ↗
5. Redox‐induced stabilization of AMBRA1 by USP7 promotes intestinal oxidative stress and colitis through antagonizing DUB3‐mediated NRF2 deubiquitination10.1002/advs.202411320 ↗
6. Reactive oxygen species-responsive polymer drug delivery system targeted oxidative stressed colon cells to ameliorate colitis10.1021/acsnano.4c14373 ↗
7. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis10.1136/gutjnl-2018-317571 ↗
8. The first international rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease10.1136/gutjnl-2023-329948 ↗
9. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages10.1016/j.immuni.2018.12.018 ↗
10. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity10.1038/s41591-022-01680-y ↗
11. ECCO-ESGAR-ESP-IBUS guideline on diagnostics and monitoring of patients with inflammatory bowel disease: part 110.1093/ecco-jcc/jjaf106 ↗
12. The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome10.1016/j.jconrel.2024.04.016 ↗
13. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis10.1053/j.gastro.2024.10.001 ↗
14. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease10.1053/j.gastro.2021.02.068 ↗
15. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis10.1053/j.gastro.2019.08.027 ↗
16. Mirikizumab as induction and maintenance therapy for ulcerative colitis10.1056/NEJMoa2207940 ↗
17. Ozanimod as induction and maintenance therapy for ulcerative colitis10.1056/NEJMoa2033617 ↗
18. Appropriate use and complications of corticosteroids in inflammatory bowel disease: a comprehensive review10.1016/j.cgh.2025.05.019 ↗
19. Minimally invasive surgery for inflammatory bowel disease: a systematic review and meta-analysis of robotic versus laparoscopic surgical techniques10.1093/ecco-jcc/jjae037 ↗
20. Colectomy rates in ulcerative colitis: a systematic review and meta-analysis10.1016/j.dld.2022.08.039 ↗
21. British society of gastroenterology guidelines on inflammatory bowel disease in adults: 202510.1136/gutjnl-2024-334395 ↗
22. Stimuli-responsive nanomaterials for targeted drug delivery in inflammatory bowel disease: advances and emerging directions10.1016/j.matt.2025.102249 ↗
23. Oral enzyme-responsive nanoprobes for targeted theranostics of inflammatory bowel disease10.1186/s12951-024-02749-1 ↗
24. Probiotic‐enhanced porous bio‐hybrids with inflammatory targeting, ROS scavenging, and long‐term drug release for ulcerative colitis treatment10.1002/advs.202504802 ↗
25. Microfluidics-enabled polydopamine-coated selenium nanoparticles in hyaluronic hydrogel microspheres for targeted antioxidant and immunomodulatory therapy of ulcerative colitis
26. Colonic submucosa targeted delivery of probiotic and rhein for ulcerative colitis treatment10.1002/advs.71160 ↗
27. Biomimetic supramolecular assembly with IGF-1C delivery ameliorates inflammatory bowel disease (IBD) by restoring intestinal barrier integrity10.1002/advs.202403075 ↗
28. Roseburia intestinalis‐derived extracellular vesicles ameliorate colitis by modulating intestinal barrier, microbiome, and inflammatory responses10.1002/jev2.12487 ↗
29. Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases
30. Synergistic genetic and chemical engineering of probiotics for enhanced intestinal microbiota regulation and ulcerative colitis treatment10.1002/adma.202417050 ↗
31. New opportunities and old challenges in the clinical translation of nanotheranostics10.1038/s41578-023-00581-x ↗
32. Curcumin-loaded polysaccharide microparticles alleviated DSS-induced ulcerative colitis by improving intestinal microecology and regulating MAPK/NF-κB/Nrf2/NLRP3 pathways10.1016/j.ijbiomac.2024.136687 ↗
33. Folic acid-modified lactoferrin nanoparticles coated with a laminarin layer loaded curcumin with dual-targeting for ulcerative colitis treatment10.1016/j.ijbiomac.2023.123229 ↗
34. Ultrafast in situ formed robust and adhesive photo-crosslinked hydrogel encapsulating curcumin for ulcerative colitis alleviation via regulating inflammation and gut microbiota
35. Orally biomimetic metal-phenolic nanozyme with quadruple safeguards for intestinal homeostasis to ameliorate ulcerative colitis10.1186/s12951-024-02802-z ↗
36. Current understanding and translational prospects of tetrahedral framework nucleic acids10.1021/jacsau.4c01170 ↗
37. Single‐particle tracking and modulation of cell entry pathways of a tetrahedral DNA nanostructure in live cells
38. Advancements in engineering tetrahedral framework nucleic acids for biomedical innovations
39. Functionalizing framework nucleic‐acid‐based nanostructures for biomedical application10.1002/adma.202107820 ↗
40. Unveiling the potential of tetrahedral DNA frameworks in clinical medicine: mechanisms, advances, and future perspectives10.1002/smll.202410162 ↗
41. Zhang · 2026 · 393
42. Oral administration of a tetrahedral framework DNA-based nanoshot attenuates liver fibrosis via targeting galectin-310.1021/acsnano.5c05144 ↗
43. A lysosome‐activated tetrahedral nanobox for encapsulated siRNA delivery
44. Tetrahedral framework nucleic acid loaded miR‐23b inhibits synovial inflammation and cartilage matrix degradation in the treatment of rheumatoid arthritis
45. A novel bioswitchable miRNA mimic delivery system: therapeutic strategies upgraded from tetrahedral framework nucleic acid system for fibrotic disease treatment and pyroptosis pathway inhibition10.1002/advs.202305622 ↗
46. A novel mesenchymal stem cell-targeting dual-miRNA delivery system based on aptamer-functionalized tetrahedral framework nucleic acids: application to endogenous regeneration of articular cartilage
47. Framework nucleic acids loaded with quercetin: protecting retinal neurovascular unit via the protein kinase B/heme oxygenase-1 pathway10.1021/acsnano.4c05845 ↗
48. Synergistic osteogenic and antiapoptotic framework nucleic acid complexes prevent diabetic osteoporosis10.1002/adfm.202314789 ↗
49. Suppression of lipopolysaccharide‐induced sepsis by tetrahedral framework nucleic acid loaded with quercetin10.1002/adfm.202204587 ↗
50. Tetrahedral framework nucleic acids reestablish immune tolerance and restore saliva secretion in a Sjögren’s syndrome mouse model10.1021/acsami.1c14861 ↗
51. The protective effect of tetrahedral framework nucleic acids on periodontium under inflammatory conditions
52. Curcumin delivery using tetrahedral framework nucleic acids enhances bone regeneration in osteoporotic rats10.1016/j.cej.2023.144978 ↗
53. Nano shield: a new tetrahedral framework nucleic acids-based solution to radiation-induced mucositis10.1039/D2NR07174F ↗
54. Yue
55. The progression of inorganic nanoparticles and natural products for inflammatory bowel disease10.1186/s12951-023-02246-x ↗
56. Zheng · 2023 · 20 · 1367
57. Zhang · 2023 · 10 · 5474
58. PEAK1 maintains tight junctions in intestinal epithelial cells and resists colitis by inhibiting autophagy-mediated ZO-1 degradation10.1038/s41467-025-62107-z ↗
59. Tight junction structure and function revisited10.1016/j.tcb.2020.08.004 ↗
60. Macrophage‐derived extracellular vesicles‐coated palladium nanoformulations modulate inflammatory and immune homeostasis for targeting therapy of ulcerative colitis10.1002/advs.202304002 ↗
61. Coexpression of H2‐Mb and H2‐Ab genes during fetal and postnatal development10.1046/j.1365-2567.1996.d01-674.x ↗
62. Dietary suppression of MHC class II expression in intestinal epithelial cells enhances intestinal tumorigenesis10.1016/j.stem.2021.08.007 ↗
63. Sirtuins regulate macrophage polarization in heart failure: Metabolic reprogramming, epigenetic regulation, and immune cell interactions10.1016/j.phrs.2025.107936 ↗
64. Histone deacetylases as regulators of inflammation and immunity10.1016/j.it.2011.04.001 ↗
65. Restoring histone acetylation accelerates diabetic wound repair by improving the spatiotemporal dynamics of macrophages10.1002/advs.202504920 ↗
66. Promoter DNA hypermethylation and paradoxical gene activation10.1016/j.trecan.2020.02.007 ↗
67. Macrophage biology in development, homeostasis and disease10.1038/nature12034 ↗
68. Genetic control of MHC class II expression10.1016/S0092-8674(02)00696-7 ↗
69. Mitochondrial ROS production protects the intestine from inflammation through functional m2 macrophage polarization10.1016/j.celrep.2017.04.036 ↗
70. IL-10 targets IRF transcription factors to suppress IFN and inflammatory response genes by epigenetic mechanisms10.1038/s41590-025-02137-3 ↗
71. Lactobacillus rhamnosus GG induces STING-dependent IL-10 in intestinal monocytes and alleviates inflammatory colitis in mice10.1172/JCI174910 ↗
72. Interaction between drugs and the gut microbiome10.1136/gutjnl-2019-320204 ↗
73. Zhang
74. Li
75. Yan · 2025 · 53 · 1